Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.

Antonova-Koch Y, Meister S, Abraham M, Luth MR, Ottilie S, Lukens AK, Sakata-Kato T, Vanaerschot M, Owen E, Jado JC, Maher SP, Calla J, Plouffe D, Zhong Y, Chen K, Chaumeau V, Conway AJ, McNamara CW, Ibanez M, Gagaring K, Serrano FN, Eribez K, Taggard CM, Cheung AL, Lincoln C, Ambachew B, Rouillier M, Siegel D, Nosten F, Kyle DE, Gamo FJ, Zhou Y, Llinás M, Fidock DA, Wirth DF, Burrows J, Campo B, Winzeler EA.

Science. 2018 Dec 7;362(6419). pii: eaat9446. doi: 10.1126/science.aat9446.

PMID:
30523084
2.

Erratum for Brunschwig et al., "UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria".

Brunschwig C, Lawrence N, Taylor D, Abay E, Njoroge M, Basarab GS, Le Manach C, Paquet T, Gonzàlez Cabrera D, Nchinda AT, de Kock C, Wiesner L, Denti P, Waterson D, Blasco B, Leroy D, Witty MJ, Donini C, Duffy J, Wittlin S, White KL, Charman SA, Jiménez-Díaz MB, Angulo-Barturen I, Herreros E, Gamo FJ, Rochford R, Mancama D, Coetzer TL, van der Watt ME, Reader J, Birkholtz LM, Marsh KC, Solapure SM, Burke JE, McPhail JA, Vanaerschot M, Fidock DA, Fish PV, Siegl P, Smith DA, Wirjanata G, Noviyanti R, Price RN, Marfurt J, Silue KD, Street LJ, Chibale K.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01941-18. doi: 10.1128/AAC.01941-18. Print 2018 Nov. No abstract available.

3.

Defining the Determinants of Specificity of Plasmodium Proteasome Inhibitors.

Yoo E, Stokes BH, de Jong H, Vanaerschot M, Kumar T, Lawrence N, Njoroge M, Garcia A, Van der Westhuyzen R, Momper JD, Ng CL, Fidock DA, Bogyo M.

J Am Chem Soc. 2018 Sep 12;140(36):11424-11437. doi: 10.1021/jacs.8b06656. Epub 2018 Aug 29.

PMID:
30107725
4.

UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria.

Brunschwig C, Lawrence N, Taylor D, Abay E, Njoroge M, Basarab GS, Le Manach C, Paquet T, Cabrera DG, Nchinda AT, de Kock C, Wiesner L, Denti P, Waterson D, Blasco B, Leroy D, Witty MJ, Donini C, Duffy J, Wittlin S, White KL, Charman SA, Jiménez-Díaz MB, Angulo-Barturen I, Herreros E, Gamo FJ, Rochford R, Mancama D, Coetzer TL, van der Watt ME, Reader J, Birkholtz LM, Marsh KC, Solapure SM, Burke JE, McPhail JA, Vanaerschot M, Fidock DA, Fish PV, Siegl P, Smith DA, Wirjanata G, Noviyanti R, Price RN, Marfurt J, Silue KD, Street LJ, Chibale K.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00012-18. doi: 10.1128/AAC.00012-18. Print 2018 Sep. Erratum in: Antimicrob Agents Chemother. 2018 Oct 24;62(11):.

PMID:
29941635
5.

Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics.

Cowell AN, Istvan ES, Lukens AK, Gomez-Lorenzo MG, Vanaerschot M, Sakata-Kato T, Flannery EL, Magistrado P, Owen E, Abraham M, LaMonte G, Painter HJ, Williams RM, Franco V, Linares M, Arriaga I, Bopp S, Corey VC, Gnädig NF, Coburn-Flynn O, Reimer C, Gupta P, Murithi JM, Moura PA, Fuchs O, Sasaki E, Kim SW, Teng CH, Wang LT, Akidil A, Adjalley S, Willis PA, Siegel D, Tanaseichuk O, Zhong Y, Zhou Y, Llinás M, Ottilie S, Gamo FJ, Lee MCS, Goldberg DE, Fidock DA, Wirth DF, Winzeler EA.

Science. 2018 Jan 12;359(6372):191-199. doi: 10.1126/science.aan4472.

6.

Hexahydroquinolines are antimalarial candidates with potent blood-stage and transmission-blocking activity.

Vanaerschot M, Lucantoni L, Li T, Combrinck JM, Ruecker A, Kumar TRS, Rubiano K, Ferreira PE, Siciliano G, Gulati S, Henrich PP, Ng CL, Murithi JM, Corey VC, Duffy S, Lieberman OJ, Veiga MI, Sinden RE, Alano P, Delves MJ, Lee Sim K, Winzeler EA, Egan TJ, Hoffman SL, Avery VM, Fidock DA.

Nat Microbiol. 2017 Oct;2(10):1403-1414. doi: 10.1038/s41564-017-0007-4. Epub 2017 Aug 14.

7.

Macromolecular biosynthetic parameters and metabolic profile in different life stages of Leishmania braziliensis: Amastigotes as a functionally less active stage.

Jara M, Berg M, Caljon G, de Muylder G, Cuypers B, Castillo D, Maes I, Orozco MDC, Vanaerschot M, Dujardin JC, Arevalo J.

PLoS One. 2017 Jul 25;12(7):e0180532. doi: 10.1371/journal.pone.0180532. eCollection 2017.

8.

Multiplexed Spliced-Leader Sequencing: A high-throughput, selective method for RNA-seq in Trypanosomatids.

Cuypers B, Domagalska MA, Meysman P, Muylder G, Vanaerschot M, Imamura H, Dumetz F, Verdonckt TW, Myler PJ, Ramasamy G, Laukens K, Dujardin JC.

Sci Rep. 2017 Jun 16;7(1):3725. doi: 10.1038/s41598-017-03987-0.

9.

Modulation of Aneuploidy in Leishmania donovani during Adaptation to Different In Vitro and In Vivo Environments and Its Impact on Gene Expression.

Dumetz F, Imamura H, Sanders M, Seblova V, Myskova J, Pescher P, Vanaerschot M, Meehan CJ, Cuypers B, De Muylder G, Späth GF, Bussotti G, Vermeesch JR, Berriman M, Cotton JA, Volf P, Dujardin JC, Domagalska MA.

MBio. 2017 May 23;8(3). pii: e00599-17. doi: 10.1128/mBio.00599-17.

10.

Single locus genotyping to track Leishmania donovani in the Indian subcontinent: Application in Nepal.

Rai K, Bhattarai NR, Vanaerschot M, Imamura H, Gebru G, Khanal B, Rijal S, Boelaert M, Pal C, Karki P, Dujardin JC, Van der Auwera G.

PLoS Negl Trop Dis. 2017 Mar 1;11(3):e0005420. doi: 10.1371/journal.pntd.0005420. eCollection 2017 Mar.

11.

Alice in microbes' land: adaptations and counter-adaptations of vector-borne parasitic protozoa and their hosts.

Caljon G, De Muylder G, Durnez L, Jennes W, Vanaerschot M, Dujardin JC.

FEMS Microbiol Rev. 2016 Sep;40(5):664-85. doi: 10.1093/femsre/fuw018. Epub 2016 Jul 10. Review.

PMID:
27400870
12.

Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent.

Imamura H, Downing T, Van den Broeck F, Sanders MJ, Rijal S, Sundar S, Mannaert A, Vanaerschot M, Berg M, De Muylder G, Dumetz F, Cuypers B, Maes I, Domagalska M, Decuypere S, Rai K, Uranw S, Bhattarai NR, Khanal B, Prajapati VK, Sharma S, Stark O, Schönian G, De Koning HP, Settimo L, Vanhollebeke B, Roy S, Ostyn B, Boelaert M, Maes L, Berriman M, Dujardin JC, Cotton JA.

Elife. 2016 Mar 22;5. pii: e12613. doi: 10.7554/eLife.12613.

13.

Correction to Antileishmanial Activity of a Series of N(2),N(4)-Disubstituted Quinazoline-2,4-diamines.

Van Horn KS, Zhu X, Pandharkar T, Yang S, Vesely B, Vanaerschot M, Dujardin JC, Rijal S, Kyle DE, Wang MZ, Werbovetz KA, Manetsch R.

J Med Chem. 2016 Jan 28;59(2):775. doi: 10.1021/acs.jmedchem.5b00981. Epub 2016 Jan 12. No abstract available.

PMID:
26754204
14.

Experimental resistance to drug combinations in Leishmania donovani: metabolic and phenotypic adaptations.

Berg M, García-Hernández R, Cuypers B, Vanaerschot M, Manzano JI, Poveda JA, Ferragut JA, Castanys S, Dujardin JC, Gamarro F.

Antimicrob Agents Chemother. 2015 Apr;59(4):2242-55. doi: 10.1128/AAC.04231-14. Epub 2015 Feb 2.

15.

Antileishmanial activity of a series of N²,N⁴-disubstituted quinazoline-2,4-diamines.

Van Horn KS, Zhu X, Pandharkar T, Yang S, Vesely B, Vanaerschot M, Dujardin JC, Rijal S, Kyle DE, Wang MZ, Werbovetz KA, Manetsch R.

J Med Chem. 2014 Jun 26;57(12):5141-56. doi: 10.1021/jm5000408. Epub 2014 Jun 17.

16.

Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?

Vanaerschot M, Dumetz F, Roy S, Ponte-Sucre A, Arevalo J, Dujardin JC.

Expert Rev Anti Infect Ther. 2014 Aug;12(8):937-46. doi: 10.1586/14787210.2014.916614. Epub 2014 May 6. Review.

PMID:
24802998
17.

Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.

Rai K, Cuypers B, Bhattarai NR, Uranw S, Berg M, Ostyn B, Dujardin JC, Rijal S, Vanaerschot M.

MBio. 2013 Oct 8;4(5):e00611-13. doi: 10.1128/mBio.00611-13.

18.

Metabolic adaptations of Leishmania donovani in relation to differentiation, drug resistance, and drug pressure.

Berg M, Vanaerschot M, Jankevics A, Cuypers B, Maes I, Mukherjee S, Khanal B, Rijal S, Roy S, Opperdoes F, Breitling R, Dujardin JC.

Mol Microbiol. 2013 Oct;90(2):428-42. doi: 10.1111/mmi.12374. Epub 2013 Sep 11.

19.

In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis.

Prajapati VK, Sharma S, Rai M, Ostyn B, Salotra P, Vanaerschot M, Dujardin JC, Sundar S.

Am J Trop Med Hyg. 2013 Oct;89(4):750-4. doi: 10.4269/ajtmh.13-0096. Epub 2013 Aug 26.

20.

Reply to Das.

Dujardin JC, Bhattarai NR, Rai K, Vanaerschot M, Uranw S, Ostyn BA, Boelaert M, Rijal S.

Clin Infect Dis. 2013 Nov;57(9):1365-6. doi: 10.1093/cid/cit510. Epub 2013 Aug 13. No abstract available.

PMID:
23943823
21.

Drug resistance in vectorborne parasites: multiple actors and scenarios for an evolutionary arms race.

Vanaerschot M, Huijben S, Van den Broeck F, Dujardin JC.

FEMS Microbiol Rev. 2014 Jan;38(1):41-55. doi: 10.1111/1574-6976.12032. Epub 2013 Jul 22. Review.

22.

Evaluation of normalization methods to pave the way towards large-scale LC-MS-based metabolomics profiling experiments.

Ejigu BA, Valkenborg D, Baggerman G, Vanaerschot M, Witters E, Dujardin JC, Burzykowski T, Berg M.

OMICS. 2013 Sep;17(9):473-85. doi: 10.1089/omi.2013.0010. Epub 2013 Jun 29.

23.

(Post-) Genomic approaches to tackle drug resistance in Leishmania.

Berg M, Mannaert A, Vanaerschot M, Van Der Auwera G, Dujardin JC.

Parasitology. 2013 Oct;140(12):1492-505. doi: 10.1017/S0031182013000140. Epub 2013 Mar 12. Review.

PMID:
23480865
24.

Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.

Rijal S, Ostyn B, Uranw S, Rai K, Bhattarai NR, Dorlo TP, Beijnen JH, Vanaerschot M, Decuypere S, Dhakal SS, Das ML, Karki P, Singh R, Boelaert M, Dujardin JC.

Clin Infect Dis. 2013 Jun;56(11):1530-8. doi: 10.1093/cid/cit102. Epub 2013 Feb 20.

PMID:
23425958
25.

Treatment of visceral leishmaniasis: model-based analyses on the spread of antimony-resistant L. donovani in Bihar, India.

Stauch A, Duerr HP, Dujardin JC, Vanaerschot M, Sundar S, Eichner M.

PLoS Negl Trop Dis. 2012;6(12):e1973. doi: 10.1371/journal.pntd.0001973. Epub 2012 Dec 20.

26.

LC-MS metabolomics from study design to data-analysis - using a versatile pathogen as a test case.

Berg M, Vanaerschot M, Jankevics A, Cuypers B, Breitling R, Dujardin JC.

Comput Struct Biotechnol J. 2013 Feb 6;4:e201301002. doi: 10.5936/csbj.201301002. eCollection 2013. Review.

27.

Drug-resistant microorganisms with a higher fitness--can medicines boost pathogens?

Vanaerschot M, Decuypere S, Berg M, Roy S, Dujardin JC.

Crit Rev Microbiol. 2013 Nov;39(4):384-94. doi: 10.3109/1040841X.2012.716818. Epub 2012 Sep 6. Review.

PMID:
22950457
28.

Genetic markers for SSG resistance in Leishmania donovani and SSG treatment failure in visceral leishmaniasis patients of the Indian subcontinent.

Vanaerschot M, Decuypere S, Downing T, Imamura H, Stark O, De Doncker S, Roy S, Ostyn B, Maes L, Khanal B, Boelaert M, Schönian G, Berriman M, Chappuis F, Dujardin JC, Sundar S, Rijal S.

J Infect Dis. 2012 Sep 1;206(5):752-5. doi: 10.1093/infdis/jis424. Epub 2012 Jun 29.

29.

Molecular mechanisms of drug resistance in natural Leishmania populations vary with genetic background.

Decuypere S, Vanaerschot M, Brunker K, Imamura H, Müller S, Khanal B, Rijal S, Dujardin JC, Coombs GH.

PLoS Negl Trop Dis. 2012;6(2):e1514. doi: 10.1371/journal.pntd.0001514. Epub 2012 Feb 28.

30.

Genome-wide SNP and microsatellite variation illuminate population-level epidemiology in the Leishmania donovani species complex.

Downing T, Stark O, Vanaerschot M, Imamura H, Sanders M, Decuypere S, de Doncker S, Maes I, Rijal S, Sundar S, Dujardin JC, Berriman M, Schönian G.

Infect Genet Evol. 2012 Jan;12(1):149-59. doi: 10.1016/j.meegid.2011.11.005. Epub 2011 Nov 20.

31.

Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance.

Downing T, Imamura H, Decuypere S, Clark TG, Coombs GH, Cotton JA, Hilley JD, de Doncker S, Maes I, Mottram JC, Quail MA, Rijal S, Sanders M, Schönian G, Stark O, Sundar S, Vanaerschot M, Hertz-Fowler C, Dujardin JC, Berriman M.

Genome Res. 2011 Dec;21(12):2143-56. doi: 10.1101/gr.123430.111. Epub 2011 Oct 28.

32.

Antimonial resistance in Leishmania donovani is associated with increased in vivo parasite burden.

Vanaerschot M, De Doncker S, Rijal S, Maes L, Dujardin JC, Decuypere S.

PLoS One. 2011;6(8):e23120. doi: 10.1371/journal.pone.0023120. Epub 2011 Aug 1.

33.

Increased metacyclogenesis of antimony-resistant Leishmania donovani clinical lines.

Ouakad M, Vanaerschot M, Rijal S, Sundar S, Speybroeck N, Kestens L, Boel L, De Doncker S, Maes I, Decuypere S, Dujardin JC.

Parasitology. 2011 Sep;138(11):1392-9. doi: 10.1017/S0031182011001120. Epub 2011 Aug 8.

PMID:
21819638
34.

Comparative gene expression analysis throughout the life cycle of Leishmania braziliensis: diversity of expression profiles among clinical isolates.

Adaui V, Castillo D, Zimic M, Gutierrez A, Decuypere S, Vanaerschot M, De Doncker S, Schnorbusch K, Maes I, Van der Auwera G, Maes L, Llanos-Cuentas A, Arevalo J, Dujardin JC.

PLoS Negl Trop Dis. 2011 May 10;5(5):e1021. doi: 10.1371/journal.pntd.0001021.

35.

Linking in vitro and in vivo survival of clinical Leishmania donovani strains.

Vanaerschot M, Maes I, Ouakad M, Adaui V, Maes L, De Doncker S, Rijal S, Chappuis F, Dujardin JC, Decuypere S.

PLoS One. 2010 Aug 17;5(8):e12211. doi: 10.1371/journal.pone.0012211.

36.

Comparison of gene expression patterns among Leishmania braziliensis clinical isolates showing a different in vitro susceptibility to pentavalent antimony.

Adaui V, Schnorbusch K, Zimic M, Gutiérrez A, Decuypere S, Vanaerschot M, DE Doncker S, Maes I, Llanos-Cuentas A, Chappuis F, Arévalo J, Dujardin JC.

Parasitology. 2011 Feb;138(2):183-93. doi: 10.1017/S0031182010001095. Epub 2010 Aug 3.

PMID:
20678296
37.

Detection of Leptomonas sp. parasites in clinical isolates of Kala-azar patients from India.

Srivastava P, Prajapati VK, Vanaerschot M, Van der Auwera G, Dujardin JC, Sundar S.

Infect Genet Evol. 2010 Oct;10(7):1145-50. doi: 10.1016/j.meegid.2010.07.009. Epub 2010 Jul 13.

38.

Gene expression profiling of Leishmania (Leishmania) donovani: overcoming technical variation and exploiting biological variation.

Decuypere S, Vanaerschot M, Rijal S, Yardley V, Maes L, de Doncker S, Chappuis F, Dujardin JC.

Parasitology. 2008 Feb;135(2):183-94. Epub 2007 Oct 12.

Supplemental Content

Loading ...
Support Center